Mer­ck KGaA adds 350 work­ers at French site to build ca­pac­i­ty for 's­in­gle-use' tech for Covid-19 vac­cines, ther­a­pies

Ger­many’s Mer­ck KGaA has seen a growth spurt in re­cent months dri­ven by sky-high de­mand for Covid-19 drugs and vac­cines. Now, the com­pa­ny is flesh­ing out a French pro­duc­tion site to pro­duce one-and-done pro­duc­tion tech that can help Covid-19 man­u­fac­tur­ers scale up faster.

Mer­ck KGaA through its Mil­li­pore­Sig­ma sub­sidiary will in­vest near­ly $30 mil­lion and add 350 po­si­tions to its Mol­sheim, France fa­cil­i­ty to build ca­pac­i­ty for “sin­gle-use” tech­nol­o­gy, pre­assem­bled pro­duc­tion equip­ment that al­lows com­pa­nies to rapid­ly scale their own pro­duc­tion, Mer­ck KGaA said this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER